2nd Edition
Applying Genomic and Proteomic Microarray Technology in Drug Discovery
Omics and Microarrays Revisited
The Microarray Format
The Omic Era
The Role for Gene Expression Microarrays in Drug Discovery
Proteomics Today—The Great Challenge
The Potential Role for Protein Microarrays in Drug Discovery
Future Medicine—Pharmacoproteomics or Pharmacogenomics?
Commercial Microarrays
In Situ DNA Arrays
Ex Situ or Spotted DNA Arrays
Comparison of Commercial DNA Microarrays
Commercial Protein Arrays
Three-Dimensional (3D) and Four-Dimensional (4D) Chips
Flow-Thru Biochips
Electronic Biochips
Supports and Surface Chemistries
Substrates
Physical Features
Surface Chemistries
Variation in the Performance of Glass Slide-Based Antibody Microarrays
Comparison of Different Surface Chemistries for the Immobilization of Auto-Antigens
Click Chemistry as an Immobilization Strategy
Oxygen Plasma-Mediated Modification of DVD-R Disks for Tethering of Oligonucleotides
Construction of Lipid Bilayer Microarrays
Arraying Processes
Creating Spotted Microarrays
Microarray Printing Mechanisms
Microarray Pins
Other Approaches
Setting Up the Print Run
Protocols for Printing Nucleic Acids
Protocols for Printing Proteins
Newer Methods for Printing
Gene Expression: Microarray-Based Applications
Applications Demonstrating DNA Microarray Utility
Biomedical Research Applications
Micro-RNA
Array-Based Comparative Genomic Hybridization
Protein Microarray Applications
Applications Demonstrating Protein Microarray Utility
Measuring Microarray Performance
Other Microarray Formats Useful for Proteomic Applications
Dual Labeling of Targets for Increased Sensitivity and Specificity
The Depletion of Highly Abundant Proteins from Serum Deemed Unnecessary
Competitive ELISA by Protein Microarray
The Issue of Cross-Reactivity in a Protein Microarray Sandwich ELISA
Multiplex Assays
Multiplex Polymerase Chain Reaction (PCR)
Multiplex Lateral Flow
Multiplex Bead-Based Assays
Multiplex Microarrays
Adoption of Multiplex Assays
Index
Biography
Robert S. Matson is president and co-founder of QuantiScientifics, LLC. The company is involved in the commercialization of multiplexed assays for life science, clinical research, and in vitro diagnostics. Previously, Matson was involved in the research and development of microarray technologies, detection chemistries, as well as point-of-care devices for more than 17 years while at Beckman Coulter, Inc. He participated in the National Institute of Standards and Technology’s (NIST) Advanced Technology Program sponsored Genosensor Consortium and collaborated with Sir Edwin Southern on the development of an in situ oligonucleotide array synthesis platform for the corporation. Other work included development of the A2 MicroArray System, a microplate-based array platform for multiplexed micro-ELISA, which QuantiScientifics recently licensed for commercialization.
